Takeda Pharmaceutical Company Limited

Tomoya Yukawa

Satoshi Yamamoto

Tsuneo Oda

Junya Shirai

Yoshiyuki Fukase

Atsuko Ochida

Yoshihide Tomata

Naoki Ishii

Takashi Imada

Shoji Fukumoto

Mitsunori Kono

Hidekazu Tokuhara

Michiko Tawada

Ayumu Sato

Ikuo Fujimori

Tsuneo Yasuma

Makoto Kamata

Masami Yamada

Hiroyuki Watanabe

Masataka Murakami

Taku Kamei

Yusuke Sasaki

Zenichi Ikeda

Tetsuya Tsukamoto

Tohru Yamashita

Nobuki Sakauchi

Hideki Hirose

Yuji Ishichi

Ryo Mizojiri

Kazuko Yonemori

Yoshihisa Nakada

Yusuke Ohba

Takuya Fujimoto

Mitsunori Kouno

Provided are heterocyclic compounds having a ROR&#x3b3;t inhibitory action represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Heterocyclic compounds and their use as retinoid-related orphan receptor (ROR) gamma-T inhibitors

The present invention relates to compound (I) or a salt thereof which has a ROR&#x3b3;t inhibitory action. wherein each symbol is as defined in the specification.

Heterocyclic compound

The problem of the present invention is to provide a compound having a superior ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an ROR&#x3b3;t inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

The present invention provides a heterocyclic compound having an ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): whereinAr is a the partial structure (1) to the partial structure (5),Q is a bivalent group selected from the group consisting of (Ia)-(If), andB is a ring optionally having substituent(s),or a salt thereof.

The present invention provides a heterocyclic compound having a ROR&#x3b3;t inhibitory action. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.or a salt thereof.

Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.

Heterocyclic compounds

The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.

Bicyclic compound

Growing community of inventors

Kanagawa, Japan

Tomoya Yukawa